Drug Profile
RX 5902
Alternative Names: RX-5902; SupinoxinLatest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator Korea Research Institute of Chemical Technology
- Developer Ocuphire Pharma; Rexahn Pharmaceuticals
- Class Antineoplastics; Piperazines; Quinoxalines; Small molecules
- Mechanism of Action RNA helicase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Malignant melanoma; Pancreatic cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer
Most Recent Events
- 22 Aug 2023 Discontinued - Phase-I/II for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (Ocuphire Pharma pipeline, August 2023)
- 22 Aug 2023 Discontinued - Phase-II for Triple-negative-breast-cancer (Metastatic disease, Second-line therapy or greater) in USA (PO) (Ocuphire Pharma pipeline, August 2023)
- 22 Aug 2023 Discontinued - Preclinical for Renal cell carcinoma in USA (PO) (Ocuphire Pharma pipeline, August 2023)